CLINICAL TRIALS PROFILE FOR SHINGRIX
✉ Email this page to a colleague
All Clinical Trials for SHINGRIX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03771157 ↗ | Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors | Active, not recruiting | University of Rochester | Early Phase 1 | 2019-02-01 | The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors. |
| NCT04403139 ↗ | VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination | Not yet recruiting | National Institute on Aging (NIA) | Phase 4 | 2020-09-01 | To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells |
| NCT04403139 ↗ | VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination | Not yet recruiting | University of Washington | Phase 4 | 2020-09-01 | To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells |
| NCT04523246 ↗ | Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents | Recruiting | Oklahoma Medical Research Foundation | Early Phase 1 | 2020-09-01 | The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19. |
| NCT04523246 ↗ | Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents | Recruiting | Barbara Carlson | Early Phase 1 | 2020-09-01 | The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19. |
| NCT04869982 ↗ | Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years | Recruiting | GlaxoSmithKline | Phase 4 | 2021-05-14 | The purpose of this study is to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults aged 50 years and older. |
| NCT05189106 ↗ | Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial | Not yet recruiting | Holy Cross Hospital, Florida | Phase 1/Phase 2 | 2022-02-01 | This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers of an ALS-related gene, such as a hexanucleotide expansion in the C9ORF72 gene, with evidence of abnormal inflammatory signaling in cerebrospinal fluid (CSF) at baseline. Each participant will be treated with baricitinib for 24 weeks; no placebo will be given. Participants will receive baricitinib 2 mg per day by mouth for the first 8 weeks and baricitinib 4 mg per day by mouth for the remaining 16 weeks. This proof of concept trial will ascertain whether baricitinib at 2 mg per day, 4 mg per day, or both reaches therapeutic levels in the CSF and suppresses inflammatory biomarkers associated with type I interferon signaling among the study participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SHINGRIX
Condition Name
Clinical Trial Locations for SHINGRIX
Trials by Country
Clinical Trial Progress for SHINGRIX
Clinical Trial Phase
Clinical Trial Sponsors for SHINGRIX
Sponsor Name
